期刊
TRENDS IN BIOTECHNOLOGY
卷 35, 期 2, 页码 159-171出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2016.07.006
关键词
-
资金
- Jorge and Leslie Bacardi Fund for the study of Regenerative Medicine
- Mayo Clinic Center for Regenerative Medicine
- James C. and Sara K. Kennedy Award
- Mayo Clinic Center for Individualized Medicine Gerstner Family Award
- Richard D. and Darlene R. DeMars Award
- Strawn Family Award
- American Association of Neurological Surgeons-Neurosurgery Research & Education Foundation (AANS/NREF) Young Clinician Investigator Award
Nanomedicine offers unique advantages in treating human cancers. However, physiological and pathological barriers within normal and disease tissues, which are highly variable among individuals, often hinder its effectiveness. The body possesses specific innate responses to nanoparticles (NPs), which when combined with unique pathophysiological signatures in the tumor micro environment, can severely limit the utility of nanomedicine in the oncological setting. Furthermore, with the successes of cancer immunotherapies, understanding nanoimmune interactions and developing immune-smart cancer nano medicine that can take advantage of the body's immune functions will increasingly become clinically relevant. Therefore, a better understanding of the important native and acquired biological processes that dictate the fate of nanomedicine is integral to developing more effective individualized platforms for treating cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据